MyFinsight
Home
Blog
About
Proceeds from sale of
series a common stock
$175,000K
Proceeds from exercise of
stock options
$96K
Proceeds from purchases
under employee stock...
$93K
Net cash provided by
financing activities
$164,389K
Canceled cashflow
$10,800K
Net (decrease)
increase in cash and cash...
$130,875K
(490.52%↑ Y/Y)
Canceled cashflow
$33,514K
Payment of issuance
costs
$10,800K
Stock-based compensation
expense
$5,530K
Accounts payable,
accrued expenses and...
$401K
Non-cash operating lease
expense
$78K
Sales and maturities
of marketable...
$32,843K
Net cash used in
operating activities
-$19,710K
Net cash provided by
investing activities
-$13,804K
Canceled cashflow
$6,009K
Canceled cashflow
$32,843K
Net loss
-$24,603K
Purchases of marketable
securities
$46,647K
Prepaid expenses and
other current assets
$826K
Accretion of discount on
marketable securities
$157K
Operating lease
liabilities
-$78K
Other assets
$55K
Back
Back
Cash Flow
Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc. (SGMT)
source: myfinsight.com